Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 2166 word(s) 2166 2021-11-10 10:15:59 |
2 Format Change Meta information modification 2166 2021-11-11 03:20:53 | |
3 The format is correct Meta information modification 2166 2021-11-12 09:19:33 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Yadav, D. Current Potential Therapeutic Approaches against SARS-CoV-2. Encyclopedia. Available online: (accessed on 22 June 2024).
Yadav D. Current Potential Therapeutic Approaches against SARS-CoV-2. Encyclopedia. Available at: Accessed June 22, 2024.
Yadav, Dharmendra. "Current Potential Therapeutic Approaches against SARS-CoV-2" Encyclopedia, (accessed June 22, 2024).
Yadav, D. (2021, November 10). Current Potential Therapeutic Approaches against SARS-CoV-2. In Encyclopedia.
Yadav, Dharmendra. "Current Potential Therapeutic Approaches against SARS-CoV-2." Encyclopedia. Web. 10 November, 2021.
Current Potential Therapeutic Approaches against SARS-CoV-2

The ongoing SARS-CoV-2 pandemic is a serious threat to public health worldwide and, to date, no effective treatment is available. Thus, we herein review the pharmaceutical approaches to SARS-CoV-2 infection treatment. Numerous candidate medicines that can prevent SARS-CoV-2 infection and replication have been proposed. These medicines include inhibitors of serine protease TMPRSS2 and angiotensin converting enzyme 2 (ACE2). The S protein of SARS-CoV-2 binds to the receptor in host cells. ACE2 inhibitors block TMPRSS2 and S protein priming, thus preventing SARS-CoV-2 entry to host cells. Moreover, antiviral medicines (including the nucleotide analogue remdesivir, the HIV protease inhibitors lopinavir and ritonavir, and wide-spectrum antiviral antibiotics arbidol and favipiravir) have been shown to reduce the dissemination of SARS-CoV-2 as well as morbidity and mortality associated with COVID-19

therapy SARS-CoV-2 combination therapy virus-based therapy host-based therapy SARS-CoV-2 cell entry inhibitors

1. Introduction

Coronaviruses contain positive-sense, single-stranded RNA, with a genome size ranging from 26–32 kb, and five structural proteins, and are classified into four categories: alpha, beta, gamma, and delta [1][2]. Human coronaviruses are alpha and beta coronaviruses which can cause respiratory and gastrointestinal tract infections [2]. The severe acute respiratory syndrome (SARS) outbreak between November 2002 and July 2003 (nine months) resulted in more than 8000 total cases and 774 deaths, with a fatality rate of 9.6% [3]. Middle East respiratory syndrome (MERS) was reported in 2012 resulting in more than 2400 cases and 858 deaths, with a fatality rate of 34.4%. Subsequently, in late December 2019, an unspecified case of pneumonia was reported in Wuhan, Hubei Province, the People’s Republic of China [1][2][3]. COVID-19 is the official name given by the WHO to the disease caused by SARS-CoV-2 infection. It has since been observed that the virus could spread from human to human [4]. Its incubation period is 2 to 14 days with various clinical presentations: asymptomatic, mild to severe illness, and mortality [5]. Symptoms include fever, cough, difficulty breathing, malaise and fatigue, gastrointestinal symptoms (decreased appetite, vomiting, watery diarrhea, and dehydration), loss of taste and smell, sore throat, rhinorrhoea, severe pneumonia, and acute respiratory distress, which can lead to multiple organ failure and death. The SARS-CoV-2 virus is mainly spread via airborne/aerosol particles; the virus has been observed to remain viable and infective for over 3 h in the air [6][7]. SARS-CoV-2 infection is a highly communicable disease, and this pandemic has been designated a world public health emergency by the World Health Organization (WHO) [7]. However, SARS-CoV-2 has many potential natural, intermediate, and final hosts, as do other viruses; thus, major problems in the prevention and diagnosis of viral infection are raised [8]. In this paper we discuss the genetic structure of SARS-CoV-2 and its mechanism of pathogenesis. We include consideration of the phylogenetic analysis of the SARS-CoV-2 genome, multiple sequence alignment analysis, and therapeutic approaches to SAR-Co-V-2 infection.

2. SARS-CoV-2 Genetic Structure and Pathogenic Mechanism

The SARS-CoV-2 genome codes for more than 20 distinct proteins. At least four structural proteins are present in coronaviruses, namely spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins (Figure 1). S proteins, which are involved in host attachment and virus-cell membrane fusion, determine the host range for viral infection (Figure 2) [9].
Figure 1. Genome structure of SARS-CoV-2. Figure was created by using BioRender (, accessed on 15 September 2021).
Figure 2. Crystallographic structure SARS-CoV-2. Figure was created using by BioRender (, accessed on 15 September 2021).
The SARS-CoV-2 main protease (Mpro) is recognised as one of the most essential viral proteins. SARS-CoV-2 Mpro is more than 96% similar to SARS-CoV Mpro. During viral translation, SARS-CoV-2 Mpro cleaves 11 polyproteins to polypeptides that are required for transcription and replication [10]. Some of the candidate drugs that can prevent SARS-CoV-2 viral replication target Mpro, such as remdesivir, griffithsin, nafamostat, disulfiram, lopinavir/ritonavir, nelfinavir, danoprevir and favipiravir [11].

3. Phylogenetic Analysis of SARS-CoV-2 Genome

A sequence alignment and phylogenetic analysis of SARS-CoV-2 genome is shown in Figure 3. The phylogenetic tree is primarily divided into three clades [12]. Clade I consist of SARS-CoV and Bat-SL-CoV genomes which share a sequence identity ranging from 88% to 99%. Clade II consist of 13 complete genomes of coronavirus and MERS-CoV genomes which share a sequence identity from 78% to 89%. Clade III consist of 23 SARS-CoV-2 and Bat-SL-CoV complete genomes which share a sequence identity ranging from 89% to 100%; the SARS-CoV-2 genomes isolated from human samples show a sequence identity ranging from 98% to 100% [13]. A particularly interesting observation from the analysis was that there is no major divergence in the SARS-CoV-2 genome sequence of different SARS-CoV-2 virus genomes isolated from different countries, as shown in Figure 3. The sequence alignment of the SARS-CoV-1 (Bat, PDB ID: 3TNT) and the SARS-CoV-2 (human, PDB ID: 7MBI) main proteases reveals that the amino acid sequence is conserved with a sequence identity of 96%; differences between these genomes are shown in Figure 4 at specific positions [13][14].
Figure 3. The phylogenetic tree was generated using the latest complete genome sequences of different neighbors, MERS-CoV, SARS-CoV, and Bat-SL-CoV. The tree is divided into three major clades according to the grouping of clusters: Clade I: Bat-SL-CoV-2 and SARS-CoV viruses showing a close evolutionary relationship with each other. Clade II: Human and bat coronaviruses, including MERS-CoV. Clade III: All of the SARS-CoV-2 genomes isolated from humans—it was observed that these genomes show a close evolutionary relationship with Bat-SL-CoV-2.
Figure 4. Multiple sequence alignment analysis of the amino acid sequence of SARS-CoV-1 and SARS-CoV-2 Mpro. Amino acids marked underneath with an arrow represent catalytic residues; residues marked underneath with * represent substrate-binding residues of various subsites.

4. Therapeutic Approaches to SAR-COV-2 Infection

To identify therapeutic agents that are effective against SARS-CoV-2 infection, extensive research on the structure and pathogenesis of COVID-19 is in progress [15]. Therapeutic approaches to COVID-19 can be categorized into virus-based therapy and host-based therapy, as shown in Figure 5.
Figure 5. Therapeutic approaches to SARS-CoV-2 infection.

4.1. Virus-Based Therapy

Viral nucleic acids consist of nucleosides and nucleotides. Drugs capable of attacking nucleotides, nucleosides, or viral nucleic acids can affect the activity of a broad range of coronaviruses and other viruses, as shown in Table 1 [16]. Possible targets for antiviral therapy include major enzymes and proteins involved in SARS-CoV-2 viral replication. The PLpro enzymes and papain-like protease of SARS-CoV and MERS-CoV have been shown to exert proteolytic, deubiquitylating, and deISGylating activities. Studies have shown that lopinavir-ritonavir is the most potent protease inhibitor as shown in Table 1 [17]. The main SARS-CoV-2 immunogen antigen is the Spike glycoprotein with membrane anchor, which plays an important role in the interaction between host cells and viruses. Studies have shown that certain monoclonal antibodies can target the receptor binding domain (RBD) subunit epitopes and inhibit viral cell receptor binding, whereas other monoclonal antibodies bind to the S2 subunit and disrupt viral cell fusion [18]. A study using the CR3022 neutralising antibody of SARS-CoV shown in Table 1 [19]. Earlier trials also showed that adoptive transfer of plasma containing anti-MERS-COV-S antibodies had the ability to prevent infection and accelerate viral clearance.
Table 1. Virus-based therapy: Drugs capable of attacking nucleotides, nucleosides, or viral nucleic acids of a broad range of coronaviruses and other viruses.
Antiviral Agent Drug Target Mechanism of Action Infectious Disease References
Remdesivir RdRp Terminates the non-obligate chain SARS-CoV-2, MERS-CoV, SARS-CoV [20]
Favipiravir RdRp Inhibits RdRp SARS-CoV-2, Influenza [21]
siRNA RdRp Short chains of dsRNA that interfere SARS-CoV, MERS-CoVWu [22]
Galidesivir RdRp Inhibits viral RNA polymerase function by Galidesivir SARS-CoV-2, [23]
Ribavirin RdRp Inhibits viral RNA synthesis and mRNA capping SARS-CoV-2, MERS-CoV, SARS-CoV, [24]
LJ001 and JL103 Lipid membrane Membrane-binding photosensitizers that induce Enveloped viruses (IAV, filoviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses and HIV-1) [25]
CR3022 Spike glycoprotein Immunogenic antigen against Spike protein SARS-CoV-2, SARS-CoV [26]
Griffithsin Spike glycoprotein Griffithsin binds to the SARSCoV-2 spike SARS-CoV-2 [27]
Peptide (P9) Spike glycoprotein Inhibits spike protein-mediated cell-cell entry or Broad-spectrum (SARS-CoV, MERS-CoV, influenza) [28]
Nafamostat Spike glycoprotein Inhibits spike-mediated membrane fusion A SARS-CoV-2, MERS-CoV [29]
Ritonavir 3CLpro Inhibits 3CLpro SARS-CoV-2, MERS-CoV [30]
Lopinavir 3CLpro Inhibits 3CLpro SARS-CoV-2, MERS-CoV, SARS-CoV, HCoV-229E, HIV, HPV [31]
Darunavir and cobicistat 3CLpro Inhibits 3CLpro SARS-CoV-2 [32]

4.2. Host-Based Therapy

Viral entry of SARS-CoV-2 depends on the priming of its spike protein and on transmembrane protease 2 (TMPRSS2). Further studies have shown that camostat mesylate, a serine protease inhibitor, can block TMPRSS2 activity and is thus considered as a therapeutic candidate as shown in Table 2 [33]. Other research indicates a pH- and receptor-dependent endocytosis when coronavirus is introduced into the host cell. AP-2-associated protein kinase 1 (AAK1), a host kinase, controls clathrin-mediated endocytosis [34]. Since the virus structure is now established, various inhibitors have been tested in cell-based systems for their ability to prevent viral entry and replication within the host body, as shown in Table 2 [35]. These include spike (S) protein inhibitors, S-cleavage inhibitors, helicase and protease inhibitors, fusion core blockers, HCB monoclonal antibodies, RBD–ACE2 blockers, antiviral peptides, siRNAs, and antifreeze eutralizati antibodies [35][36]. The following section concentrates on the possible therapeutic treatment options based on our limited knowledge of SARS-CoV-2.
Table 2. Host-based therapy: Drug target and mechanism of action against infectious diseases.
Antiviral Agent Drug Target Mechanism of Action Infectious Disease References
Baricitinib Clathrin-mediated endocytosis Baricitinib Clathrin-mediated endocytosis [34]
Chloroquine Endosomal
A lysosomatropic base that appears to disrupt intracellular trafficking and viral fusion events SARS-CoV-2, SARS-CoV, MERS-CoV [33]
Convalescent plasma - Inhibits virus entry to the target cells SARS-CoV, SARS-CoV-2, Influenza [35][36]
Camostat Mesylate Surface protease Potent serine protease inhibitor SARS-CoV, MERS-CoV, HcoV-229E [33]
Corticosteroids Pulsed methylprednisolone Patients with severe MERS who were treated with systemic corticosteroid with or without antivirals and interferons had no favorable response SARS-CoV, MERS-CoVL [35]
Nitazoxanide Interferon response Induces the host innate immune response Coronaviruses, SARS-CoV-2 [19]
Recombinant interferons Interferon response Exogenous interferons SARS-CoV-2, SARS-CoV, MERS-CoV [37]

4.2.1. Neutralizing Antibodies

In general, coronavirus infection begins with the entry of the viral S protein, which binds to the cell surface. This S protein fuses with the cell membrane and facilitates the syncytial development and transmission of viral nucleocapsids into the cell for further replication [35]. Studies have shown that neutralization of the S protein RBD of SARS-CoV [36] and MERS-CoV [38][39][40] by antibodies can be effective against these diseases. Neutralisation of antigens can be highly useful in COVID-19 treatment, given that the S protein RBD sequence of SARS-CoV-2 is similar to those of SARS-CoV and MERS-CoV [37]. Critical COVID-19 patients are currently treated with immunoglobulin G [35][36]. FcR plays a role in inflammation in the lung; therefore, inflammation in COVID-19 can be reduced by blocking FcR activation. Thus, intravenous administration of immunoglobulins can be effective in the treatment of pulmonary inflammation, as shown in Table 3 and Figure 6 [41].
Figure 6. Schematic of binding mechanism of SARS-CoV-2 spike protein to the receptor.
Table 3. Neutralizing antibodies against SARS-CoV-2.
S.N. Antibody Name Antibody Type Origin PDB ID Epitopes Neutralizing Mechanism Cross Neutralizing Activity Protective Efficacy Ref
1 CV30 Human IgG Infected COVID-19 patients 6XE1 D420-Y421, Y453, L455-N460, Y473-S477, F486-N487, Y489, Q493, T500, G502, Y505 Block hACE2-RBD interaction no IC50 value of 0.03 µg/mL [35]
2 REGN10933 Recombinant full-human antibodies Humanized mice and COVID-19-convalescent patients 6XDG R403, K417, Y421, Y453, L455-F456, A475-G476, E484-Y489, Q493 Block hACE2-RBD interaction, ADCC & ADCP no IC50 value of 37.4 pM  
3 B38 Human IgG COVID-19-convalescent patient 7BZ5 R403, D405-E406, Q409, D420-Y421, Y452, L454-N460, Y473-S477, F486-N487, Y489-F490, Q493-G496, Q498, T500-V503, Y505 Block hACE2-RBD interaction no A single dose of B38 (25 mg/kg) [35]
4 CC12.1 Human IgG COVID-19-convalescent patient 6XC3 R403, D405-E406, R408-Q409, D420-Y421, Y453, L455-N460, Y473-S477, F486-N487, Y489, Q493-G496, Q498, T500-V503, Y505 Block hACE2-RBD interaction no IC50 value of 0.019 µg/mL [36]
5 CB6 Human IgG COVID-19-convalescent patient 7C01 R403, D405-E406, R408-Q409, D420-Y421, L455-N460, Y473-S477, F486-N487, Y489, Q493, Y495, N501-G502, G504-Y505 Block hACE2-RBD interaction no A single dose of CB6-LALA (50 mg/kg) [37]
6 C105 Human IgG COVID-19-convalescent patient 6XCN, 6XCM R403, D405, R408, D420-Y421, Y453, L455-N460, Y473, A475-G476, F486-N487, G502, Y505 Block hACE2-RBD interaction no IC50 value of 26.1 ng/mL [41]
7 CC12.3 Human IgG COVID-19-convalescent patient 6XC7 R403, D405, D420-Y421, Y453, L455-N460, Y473-S477, F486-N487, Y489, Q493, G496, N501, Y505 Block hACE2-RBD interaction no IC50 value of 0.018 µg/mL [42]
8 CR3022 Human IgG SARS-convalescent patient 6YOR, 6 W41 Y369-N370, F374-K386, L390, F392, D428, T430, F515-L517 Trapping RBD in the less stable up conformation while leading to destabilization of S SARS-CoV, SARS-CoV-2 ND50 value of 0.114 µg/mL [19]
9 EY6A Human IgG Late-stage COVID-19 patient 6ZDH, 6ZER, 6ZCZ Y369, F374-S375, F377-K386, N388, L390, P412-G413, D427-F429, L517 destabilization of S SARS-CoV, SARS-CoV-2 ND50 value of ~10.8 µg/mL [26]
10 VHH-72 Llama single domain antibody llama immunized with prefusionstabilized betacoronavirus spikes 6WAQ Y356-T359, F361-C366, A371-T372, G391-D392, R395, N424, I489, Y494 Trapping RBD in the less stable up conformation while leading to destabilization of S, Block hACE2_RBD interaction SARS-CoV, SARS-Co-V-2 IC50 values of 0.14 µg/mL and 0.2 mg/mL. [19]
11 BD23 Human IgG COVID-19-convalescent patient 7BYR G446, Y449, L452, T470, E484-F486, Y489-F490, L492-S494, G496, Q498, T500-N501, Y505 Block hACE-RBD2 interaction no IC50 value of 8.5 µg/mL [26]
12 Fab 2–4 Human IgG Infected COVID-19 patients 6XEY Y449, Y453, L455-F456, E484-F486, Y489-F490, L492-S494, G496 Locking RBD in the down conformation while occluding access to ACE2 no Neutralizing SARS-CoV-2 live virus with IC50 value of 0.057 µg/mL [41]


  1. Nadeem, M.S.; Zamzami, M.A.; Choudhry, H.; Murtaza, B.N.; Kazmi, I.; Ahmad, H.; Shakoori, A.R. Origin, potential therapeutic targets and treatment for coronavirus disease (COVID-19). Pathogens 2020, 9, 307.
  2. Zhang, Y.Z.; Holmes, E.C. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell 2020, 181, 223–227.
  3. Lai, C.C.; Liu, Y.H.; Wang, C.Y.; Wang, Y.H.; Hsueh, S.C.; Yen, M.Y.; Ko, W.C.; Hsueh, P.R. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J. Microbiol. Immunol. Infect. 2020, 53, 404–412.
  4. Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020, 46, 846–848.
  5. Tian, Y.; Rong, L.; Nian, W.; He, Y. Review article: Gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment. Pharmacol. Ther. 2020, 51, 843–851.
  6. Davies, N.G.; Klepac, P.; Liu, Y.; Prem, K.; Jit, M.; CMMID COVID-19 Working Group; Eggo, R.M. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat. Med. 2020, 26, 1205–1211.
  7. Khan, S.; Siddique, R.; Shereen, M.A.; Ali, A.; Liu, J.; Bai, Q.; Bashir, N.; Xue, M. Emergence of a novel Coronavirus, severe acute respiratory syndrome Coronavirus 2: Biology and therapeutic options. J. Clin. Microbiol. 2020, 58, e00187-20.
  8. Singh, D.D.; Jain, A. Multipurpose Instantaneous Microarray Detection of Acute Encephalitis Causing Viruses and Their Expression Profiles. Curr. Microbiol. 2012, 65, 290–303.
  9. Wan, Y.; Shang, J.; Graham, R.; Baric, R.S.; Li, F. Receptor recognition by the novel Coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS Coronavirus. J. Virol. 2020, 94, e00127-20.
  10. Ton, A.T.; Gentile, F.; Hsing, M.; Ban, F.; Cherkasov, A. Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds. Mol. Inform. 2020, 10, 202000028.
  11. Pan, H.; Peto, R.; Henao-Restrepo, A.-M.; Karim, Q.A.; Alejandria, M.; García, C.H.; Kieny, M.-P.; Malekzadeh, R.; Murthy, S.; Preziosi, M.-P.; et al. Repurposed antiviral drugs for COVID-19—Interim WHO Solidarity Trial Results. N. Engl. J. Med. 2021, 384, 497–511.
  12. Lam, T.T.-Y.; Shum, M.H.-H.; Zhu, H.-C.; Tong, Y.-G.; Ni, X.-B.; Liao, Y.-S.; Wei, W.; Cheung, W.Y.-M.; Li, W.-J.; Li, L.-F.; et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature 2020, 583, 282–285.
  13. Khateeb, J.; Li, Y.; Zhang, H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit. Care 2021, 25, 244.
  14. Monteil, V.; Kwon, H.; Patricia, P.; Prado, P.; Hagelkrüys, A.; Wimmer, R.A.; Stahl, M.; Leopoldi, A.; Garreta, E.; Hurtado del Pozo, C.; et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell Press 2020, 181, 905–913.
  15. Zhou, Y.; Hou, Y.; Shen, J.; Huang, Y.; Martin, W.; Cheng, F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020, 6, 14–18.
  16. Rabaan, A.A.; Al-Ahmed, S.H.; Haque, S.; Sah, R.; Tiwari, R.; Malik, Y.S.; Dhama, K.; Yatoo, M.I.; Bonilla-Aldana, D.K.; RodriguezMorales, A.J.; et al. SARS-CoV-2, SARS-CoV, and MERS-CoV: A comparative overview. Infez. Med. 2020, 28, 174–184.
  17. Ko, M.; Chang, S.; Byun, S.; Ianevski, A.; Choi, I.; D’Orengiani, A.-L.P.H.D.; Ravlo, E.; Wang, W.; Bjørås, M.; Kainov, D.; et al. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical isolate from South korea identifies potential therapeutic options for COVID-19. Viruses 2021, 13, 651.
  18. Yadav, R.; Chaudhary, J.; Jain, N.; Chaudhary, P.; Khanra, S.; Dhamija, P.; Sharma, A.; Kumar, A.; Handu, S. Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells 2021, 10, 821.
  19. Finkelstein, M.T.; Mermelstein, A.G.; Parker Miller, E.; Seth, P.C.; Stancofski, E.D.; Fera, D. Structural analysis of neutralizing epitopes of the SARS-CoV-2 spike to guide therapy and vaccine design strategies. Viruses 2021, 13, 134.
  20. Lai, C.-C.; Chen, C.-H.; Wang, C.-Y.; Chen, K.-H.; Wang, Y.-H.; Hsueh, P.-R. Clinical efficacy and safety of remdesivir in patients with COVID-19: A systematic review and network meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 2021, 76, 1962–1968.
  21. Kocayiğit, H.; Süner, K.Ö.; Tomak, Y.; Demir, G.; Yaylacı, S.; Dheir, H.; Güçlü, E.; Erdem, A.F. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. J. Clin. Pharm. Ther. 2021, 46, 454–459.
  22. Saw, P.E.; Song, E.-W. siRNA therapeutics: A clinical reality. Sci. China Life Sci. 2020, 63, 485–500.
  23. Zanella, I.; Zizioli, D.; Castelli, F.; Quiros-Roldan, E. Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-CoV-2 infection. Pharmaceuticals 2021, 14, 454.
  24. Dejmek, M.; Konkol’ová, E.; Eyer, L.; Straková, P.; Svoboda, P.; Šála, M.; Krejčová, K.; Růžek, D.; Boura, E.; Nencka, R. Non-Nucleotide RNA-Dependent RNA Polymerase Inhibitor That Blocks SARS-CoV-2 Replication. Viruses 2021, 13, 1585.
  25. Singh, D.D.; Han, I.; Choi, E.H.; Yadav, D.K. Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2. Comput. Struct. Biotechnol. J. 2020, 18, 3774–3787.
  26. Hurt, A.; Wheatley, A. Neutralizing antibody therapeutics for COVID-19. Viruses 2021, 13, 628.
  27. Li, X.; Zhang, L.; Chen, S.; Ouyang, H.; Ren, L. Possible targets of Pan-coronavirus antiviral strategies for emerging or re-emerging Coronaviruses. Microorganisms 2021, 9, 1479.
  28. Stoddard, S.V.; Wallace, F.E.; Stoddard, S.D.; Cheng, Q.; Acosta, D.; Barzani, S.; Bobay, M.; Briant, J.; Cisneros, C.; Feinstein, S.; et al. In silico design of peptide-based SARS-CoV-2 fusion inhibitors that target wt and mutant versions of SARS-CoV-2 HR1 Domains. Biophysica 2021, 1, 311–327.
  29. Yamamoto, M.; Kiso, M.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Imai, M.; Takeda, M.; Kinoshita, N.; Ohmagari, N.; Gohda, J.; Semba, K.; et al. The anticoagulant nafamostat potently inhibits SARS-CoV-2 s protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses 2020, 12, 629.
  30. Sardanelli, A.M.; Isgrò, C.; Palese, L.L. SARS-CoV-2 main protease active site ligands in the human metabolome. Molecules 2021, 26, 1409.
  31. Citarella, A.; Scala, A.; Piperno, A.; Micale, N. SARS-CoV-2 Mpro: A potential target for peptidomimetics and small-molecule inhibitors. Biomolecules 2021, 11, 607.
  32. Riva, A.; Conti, F.; Bernacchia, D.; Pezzati, L.; Sollima, S.; Merli, S.; Siano, M.; Lupo, A.; Rusconi, S.; Cattaneo, D.; et al. Da-runavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacol. Res. 2020, 157, 104826.
  33. Nersisyan, S.; Shkurnikov, M.; Turchinovich, A.; Knyazev, E.; Tonevitsky, A. Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2. PLoS ONE 2020, 15, e0235987.
  34. Gatti, M.; Turrini, E.; Raschi, E.; Sestili, P.; Fimognari, C. Janus kinase inhibitors and Coronavirus dDisease (COVID)-19: Rationale, clinical evidence and safety issues. Pharmaceuticals 2021, 14, 738.
  35. Arisan, E.D.; Dart, A.; Grant, G.H.; Arisan, S.; Cuhadaroglu, S.; Lange, S.; Uysal-Onganer, P. The prediction of miRNAs in SARS-CoV-2 genomes: Hsa-miR databases identify 7 Key miRs linked to host responses and virus pathogenicity-related KEGG pathways significant for comorbidities. Viruses 2020, 12, 614.
  36. Chien, M.; Anderson, T.K.; Jockusch, S.; Tao, C.; Li, X.; Kumar, S.; Russo, J.J.; Kirchdoerfer, R.N.; Ju, J. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. J. Proteome Res. 2020, 19, 4690–4697.
  37. Belouzard, S.; Millet, J.K.; Licitra, B.N.; Whittaker, G.R. Mechanisms of Coronavirus cell entry mediated by the viral spike protein. Viruses 2012, 4, 1011–1033.
  38. Gil Martínez, V.; Avedillo Salas, A.; Santander Ballestín, S. Antiviral therapeutic approaches for SARS-CoV-2 infection: A systematic review. Pharmaceuticals 2021, 14, 736.
  39. Janik, E.; Niemcewicz, M.; Podogrocki, M.; Saluk-Bijak, J.; Bijak, M. Existing drugs considered as promising in COVID-19 therapy. Int. J. Mol. Sci. 2021, 22, 5434.
  40. Malhani, A.A.; Enani, M.A.; Sharif-Askari, F.S.; Alghareeb, M.R.; Bin-Brikan, R.T.; AlShahrani, S.A.; Halwani, R.; Tleyjeh, I.M. Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study. PLoS ONE 2021, 16, e0252984.
  41. Jonsdottir, H.R.; Bielecki, M.; Siegrist, D.; Buehrer, T.W.; Züst, R.; Deuel, J.W. Titers of neutralizing antibodies against SARS-CoV-2 are independent of symptoms of non-severe COVID-19 in young adults. Viruses 2021, 13, 284.
  42. Magro, P.; Zanella, I.; Pescarolo, M.; Castelli, F.; Quiros-Roldan, E. Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. Biomed. J. 2021, 44, 43–53.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 528
Revisions: 3 times (View History)
Update Date: 12 Nov 2021
Video Production Service